Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Gossamer Bio in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer expects that the company will post earnings per share of ($0.72) for the year. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.
Gossamer Bio (NASDAQ:GOSS – Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. The company had revenue of $9.48 million during the quarter, compared to the consensus estimate of $4.52 million.
Get Our Latest Stock Analysis on Gossamer Bio
Gossamer Bio Stock Down 1.8 %
NASDAQ GOSS opened at $0.89 on Wednesday. Gossamer Bio has a 1-year low of $0.50 and a 1-year high of $1.60. The company has a market capitalization of $200.74 million, a price-to-earnings ratio of -2.77 and a beta of 1.81. The stock’s 50 day moving average is $0.84 and its two-hundred day moving average is $0.91. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64.
Institutional Investors Weigh In On Gossamer Bio
Several hedge funds and other institutional investors have recently made changes to their positions in GOSS. US Bancorp DE bought a new position in Gossamer Bio in the third quarter valued at about $39,000. GSA Capital Partners LLP acquired a new position in Gossamer Bio during the 3rd quarter valued at about $67,000. Algert Global LLC bought a new position in shares of Gossamer Bio in the 2nd quarter valued at about $75,000. Sequoia Financial Advisors LLC grew its position in shares of Gossamer Bio by 26.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock worth $117,000 after buying an additional 25,000 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Gossamer Bio by 67.4% during the second quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company’s stock worth $279,000 after buying an additional 124,913 shares during the last quarter. 81.23% of the stock is owned by institutional investors and hedge funds.
Gossamer Bio Company Profile
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Further Reading
- Five stocks we like better than Gossamer Bio
- How to Effectively Use the MarketBeat Ratings Screener
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.